Meros Investment Management LP Buys New Holdings in Sensus Healthcare, Inc. $SRTS

Key Points

• Meros Investment Management LP acquired 88,478 shares of Sensus Healthcare, Inc. for approximately $419,000, representing a 0.54% stake in the company.
• Sensus Healthcare's stock price fell by 2.6% to $3.35, with a twelve-month high of $9.33 and a low of $3.03.
• The company reported a loss of $0.06 earnings per share for the last quarter, missing the analyst estimate of $0.01, and had revenue of $7.32 million, below expectations of $9.30 million.

Meros Investment Management LP acquired a new stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 88,478 shares of the company's stock, valued at approximately $419,000. Meros Investment Management LP owned 0.54% of Sensus Healthcare as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in SRTS. American Century Companies Inc. raised its position in Sensus Healthcare by 12.7% in the 1st quarter. American Century Companies Inc. now owns 22,440 shares of the company's stock worth $106,000 after purchasing an additional 2,520 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Sensus Healthcare in the fourth quarter valued at approximately $27,000. Sachetta LLC increased its position in shares of Sensus Healthcare by 4.1% in the 1st quarter. Sachetta LLC now owns 124,887 shares of the company's stock valued at $591,000 after buying an additional 4,945 shares in the last quarter. Chapin Davis Inc. lifted its stake in Sensus Healthcare by 50.0% in the first quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock valued at $71,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Barclays PLC acquired a new stake in Sensus Healthcare in the 4th quarter valued at about $35,000. 25.30% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SRTS has been the topic of several research reports. Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wall Street Zen cut Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Sunday, June 22nd. Maxim Group lowered their price target on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, HC Wainwright cut their target price on shares of Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $8.00.

Sensus Healthcare Stock Up 2.3%

SRTS stock traded up $0.0750 during trading on Wednesday, reaching $3.2750. The stock had a trading volume of 62,413 shares, compared to its average volume of 190,377. The company has a market capitalization of $53.84 million, a price-to-earnings ratio of -54.58 and a beta of 1.34. The company's 50 day moving average is $4.61 and its two-hundred day moving average is $4.81. Sensus Healthcare, Inc. has a one year low of $3.03 and a one year high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.07). The company had revenue of $7.32 million during the quarter, compared to the consensus estimate of $9.30 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. As a group, research analysts predict that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.